WO2025178019A1 - 繊毛病治療用医薬組成物 - Google Patents

繊毛病治療用医薬組成物

Info

Publication number
WO2025178019A1
WO2025178019A1 PCT/JP2025/005361 JP2025005361W WO2025178019A1 WO 2025178019 A1 WO2025178019 A1 WO 2025178019A1 JP 2025005361 W JP2025005361 W JP 2025005361W WO 2025178019 A1 WO2025178019 A1 WO 2025178019A1
Authority
WO
WIPO (PCT)
Prior art keywords
syndrome
kinase
mak
substance
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/005361
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
貴久 古川
太郎 茶屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Osaka
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Priority to JP2026502615A priority Critical patent/JPWO2025178019A1/ja
Publication of WO2025178019A1 publication Critical patent/WO2025178019A1/ja
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • Ciliopathy includes retinal degeneration, choroidal coloboma, coloboma, retinitis pigmentosa, cone-rod dystrophy, cone dystrophy, macular dystrophy, corneal abnormalities, visual impairment, Leber's congenital amaurosis, Leber's amaurosis, Stargardt disease, hyperopia, keratoconus, photophobia, cataract, ptosis, nystagmus, microphthalmia, hypertelorism, cyclopia, hydrocephalus, macrocephaly, agenesis of the corpus callosum, holoprosencephaly, cerebellar vermis agenesis, cerebellar malformation and dysfunction, occipital meningocele, hypoplastic medulloblastoma, hypothalamic hamartoma, lower brainstem malformation, pituitary gland abnormalities, hypopituitarism, tumors and/or cysts in the central nervous system, brain abnormalities, epil
  • FIG. 1 shows the schedule for subretinal injection of adeno-associated virus (AAV) and retinal harvesting.
  • B shows the results of immunostaining sections of the harvested retina with anti-FLAG antibody and anti-rhodopsin antibody.
  • C shows the results of quantification of the immunofluorescent signal of rhodopsin detected inside photoreceptors.
  • Figure 1 shows the results of administering a fibroblast growth factor receptor (FGFR) inhibitor (BGJ398) to Mak-deficient mice.
  • FGFR fibroblast growth factor receptor
  • A shows the drug administration schedule.
  • B shows representative toluidine blue-stained images of Mak-/- mouse retinas administered with BGJ398 or vehicle.
  • C shows the results of measuring the thickness of the outer nuclear layer (ONL).
  • FIG. 1 shows the results of preparing shRNA expression constructs against the dynein motor protein Dync2li1 and comparing the expression-suppressing effects.
  • A shows the results of overexpressing Ick in Dync2li1 knockdown cells.
  • NIH3T3 cells were cotransfected with plasmids encoding control-shRNA or Dync2li1-shRNA3 and plasmids encoding FLAG-tagged Ick or FLAG-tagged EGFP, and immunostained with DAPI, anti-FLAG, and anti-AcTub antibodies.
  • B shows the results of measuring the length of cilia stained with anti-AcTub in FLAG-positive cells.
  • Figure 1 shows the results of inhibiting FGFR activity in Dync2li1 knockdown cells.
  • A Cells were treated with DMSO or an FGFR inhibitor (BGJ398) for 24 hours and then immunostained with anti-FLAG and anti-AcTub antibodies.
  • FIG. 1 shows the results of measuring the length of cilia stained with anti-AcTub antibodies in FLAG-positive cells.
  • Figure 1 shows the results of inhibiting FGFR activity in Dync2li1 knockdown cells.
  • A Cells were treated with DMSO or an FGFR inhibitor (AZD4547) for 24 hours and then immunostained with anti-FLAG and anti-AcTub antibodies.
  • B The length of cilia stained with anti-AcTub antibodies was measured in FLAG-positive cells.
  • Figure 1 shows the results of overexpressing a dominant-negative FGFR1 (Fgfr1-A645V) in Dync2li1 knockdown cells.
  • FIG. 1 shows the results of immunostaining with anti-FLAG and anti-AcTub antibodies.
  • B shows the results of measuring the length of cilia stained with anti-AcTub antibodies in FLAG-positive cells. Figures show the results of analyzing the effects of Ick overexpression and Mak overexpression on hedgehog signaling abnormalities.
  • A A schematic diagram of a construct expressing NanoLuc luciferase under the control of 8xGli1 binding sites and a minimal promoter.
  • C Luciferase activity was measured in NIH3T3 cells with Dync2li1 knockdown and Mak iso1 or Mak iso2 overexpression. These figures show the results of retinal observations in retina-specific Ccrk-deficient (Ccrk CKO) mice.
  • A Representative toluidine blue stained images of control and Ccrk CKO mouse retinas at 14 days of age (P14) and 1 month of age (1M).
  • B Measurement of the thickness of the outer nuclear layer (ONL).
  • Retinal sections were prepared from 14-day-old (P14) wild-type and Ccrk CKO mice and immunostained with DAPI and anti-IFT88 and anti-AcTub antibodies (top row), anti-Mak and anti-AcTub antibodies (middle row), or anti-IFT88 and anti-Cep164 antibodies (bottom row).
  • This figure shows the results of Western blot analysis of Mak phosphorylation levels in the retinas of Ccrk CKO mice.
  • (A) shows the results of overexpressing Ccrk in Dync2li1 knockdown cells.
  • NIH3T3 cells were cotransfected with a plasmid encoding Control-shRNA or Dync2li1-shRNA3 and a plasmid expressing FLAG-tagged Ccrk or FLAG-tagged EGFP, and immunostained with DAPI, anti-FLAG, and anti-AcTub antibodies.
  • B shows the results of measuring the length of cilia stained with anti-AcTub in FLAG-positive cells.
  • FIG. 1 shows the results of measuring luciferase activity in NIH3T3 cells in which Dync2li1 was knocked down and Ccrk was overexpressed.
  • the present invention provides a substance that promotes the expression or function of male germ cell-associated kinase (hereinafter referred to as Mak) and/or intestinal cell kinase (hereinafter referred to as Ick), or a pharmaceutical composition for treating ciliopathy containing Mak and/or Ick as active ingredients.
  • Mak male germ cell-associated kinase
  • Ick intestinal cell kinase
  • Ciliopathy is a group of diseases in humans characterized by abnormalities in development and sensory organs, and is known to be caused by a malfunction in the development or function of cilia, i.e., ciliopathy. Therefore, in the present invention, ciliopathy is not particularly limited as long as it is a disease or symptom caused by ciliopathy.
  • ciliary diseases include retinal degeneration, choroidal coloboma, retinitis pigmentosa, cone-rod dystrophy, cone dystrophy, macular dystrophy, corneal abnormalities, visual impairment, Leber congenital amaurosis, Leber amaurosis, Stargardt disease (juvenile macular degeneration), hyperopia, keratoconus, photophobia, cataracts, ptosis, nystagmus, microphthalmia, ocular hypertelorism, cyclopia, hydrocephalus, macrocephaly, agenesis of the corpus callosum, holoprosencephaly, cerebellar vermis defects, cerebellar malformations and dysfunction, and occipital meninges.
  • Occipital meningoceles desmoplastic medulloblastoma, hypothalamic hamartoma, lower brainstem dysplasia, pituitary gland abnormalities, hypopituitarism, tumors and/or cysts in the central nervous system, brain abnormalities, epileptic seizures, psychomotor developmental delay, neuropsychiatric dysfunction, intellectual disability, learning disabilities, behavioral disorders, motor developmental delay, ataxia, feeding disorders, cranioectodermal dysplasia, craniosynostosis, facial and digital (toe) anomalies, Weyers acrofacial dysostosis (W AD), polydactyly, brachymelia, syndactyly, missing fingers, skeletal and ectodermal defects, disorders of bone development, pelvic malformations, spinal anomalies, dental anomalies, bronchiectasis, airway anomalies, pulmonary hypoplasia, pulmonary dysplasia, disorders of lung development and expansion, respiratory disorders, Jeune-
  • the ciliopathy to be treated with the pharmaceutical composition of the present invention may be a retinal degenerative disease.
  • Retinal degenerative diseases include retinitis pigmentosa, cone-rod dystrophy, cone dystrophy, macular dystrophy, Leber's congenital amaurosis, Leber's amaurosis, and Stargardt disease. Retinitis pigmentosa is preferred.
  • a substance that promotes the expression of Mak and/or Ick may be a substance that promotes the expression of the Mak gene and/or Ick gene, or may be a substance that promotes the expression of the Mak protein and/or Ick protein.
  • a substance that promotes the expression of the Mak gene and/or Ick gene includes a nucleic acid or polynucleotide encoding Mak and/or Ick.
  • polynucleotides encoding Mak and/or Ick include, but are not limited to, DNA containing all or part of a DNA consisting essentially of the nucleotide sequence of the entire coding region of human MAK (GenBank accession number: AF505623, SEQ ID NO: 1), the nucleotide sequence of the entire coding region of mouse Mak (GenBank accession number: X66983, SEQ ID NO: 2), the nucleotide sequence of the entire coding region of human ICK (GenBank accession number: AF225919, SEQ ID NO: 3), and the nucleotide sequence of the entire coding region of mouse Ick (GenBank accession number: AF225918, SEQ ID NO: 4).
  • a substance that promotes the function of Mak and/or Ick may be a substance that promotes the phosphorylation of Mak and/or Ick, or a substance that promotes the phosphorylation of a downstream factor of Mak and/or Ick.
  • a substance that promotes the phosphorylation of a downstream factor of Mak and/or Ick may be a substance that inhibits the dephosphorylation of a downstream factor of Mak and/or Ick.
  • a representative downstream factor of Mak and/or Ick is kinesin family 3A protein (hereinafter referred to as Kif3a).
  • a substance that promotes the phosphorylation of Mak and/or Ick may be an upstream regulatory factor of Mak and/or Ick, an activator of an upstream regulatory factor of Mak and/or Ick, or a substance that inhibits the dephosphorylation of Mak and/or Ick.
  • An activator of an upstream regulatory factor of Mak and/or Ick may be a substance that promotes the expression or function of an upstream regulatory factor of Mak and/or Ick.
  • a substance that promotes the expression or function of an upstream regulatory factor of Mak and/or Ick may be the upstream regulatory factor of Mak and/or Ick itself.
  • an upstream regulatory factor of Mak and/or Ick is cell cycle-related kinase (hereinafter referred to as Ccrk).
  • a substance that promotes the expression of an upstream regulatory factor of Mak and/or Ick includes a nucleic acid or polynucleotide encoding Ccrk.
  • polynucleotides encoding Ccrk include, but are not limited to, DNAs containing all or part of DNA consisting essentially of the nucleotide sequence of the entire coding region of human CCRK (GenBank accession number: AF035013, SEQ ID NO: 5) and the nucleotide sequence of the entire coding region of mouse Ccrk (GenBank accession number: AY005133, SEQ ID NO: 6).
  • CKO retina-specific Ccrk conditional knockout mice
  • DNA that essentially consists of refers to DNA consisting of the specific base sequence described above, as well as DNA consisting of a base sequence that can hybridize with DNA consisting of the specific base sequence described above under highly stringent conditions. Stringent conditions can be calculated by applying appropriate formulas used in the field based on the desired homology, the length of the oligonucleotide, etc. In addition, techniques for substituting or deleting any base in the base sequence described above (e.g., in vitro mutagenesis, site-directed mutagenesis, etc.) may also be used.
  • An expression vector functionally containing a polynucleotide encoding Mak and/or Ick can be obtained by inserting the polynucleotide encoding Mak and/or Ick into a plasmid vector, phage vector, or the like, capable of replicating or autonomously replicating in various prokaryotic and/or eukaryotic host cells, using appropriate restriction enzyme sites.
  • "Functionally” means that the gene (DNA) is positioned so that it can be transcribed in a host cell compatible with the vector and the encoded protein can be produced.
  • the vector has an expression cassette in which a promoter region, an initiation codon, a polynucleotide encoding Mak and/or Ick, a stop codon, and a terminator region are consecutively arranged.
  • the vector may further contain a selection marker gene for selecting transformants. The same can be done with an expression vector functionally containing a polynucleotide encoding Ccrk.
  • the expression vector is not particularly limited and may be either a non-viral vector or a viral vector.
  • a non-viral vector known techniques can be used, such as methods of introducing nucleic acid molecules using liposomes (liposome method, HVJ-liposome method, cationic liposome method, lipofection method, lipofectamine method, etc.), microinjection, or methods of transferring nucleic acid molecules into cells together with carriers (metal particles) using a gene gun.
  • liposome method liposome method, HVJ-liposome method, cationic liposome method, lipofection method, lipofectamine method, etc.
  • microinjection or methods of transferring nucleic acid molecules into cells together with carriers (metal particles) using a gene gun.
  • viral vectors such as recombinant adenoviruses and retroviruses can be used.
  • Genes can be introduced into cells or tissues by introducing a polynucleotide encoding Mak and/or Ick or a polynucleotide encoding Ccrk into a DNA or RNA virus such as a detoxified retrovirus, adenovirus, adeno-associated virus (AAV), herpesvirus, vaccinia virus, poxvirus, poliovirus, Sindbis virus, Sendai virus, or SV40, and then infecting the cells or tissues with this recombinant virus.
  • a DNA or RNA virus such as a detoxified retrovirus, adenovirus, adeno-associated virus (AAV), herpesvirus, vaccinia virus, poxvirus, poliovirus, Sindbis virus, Sendai virus, or SV40
  • the presence or absence and degree of increase in the transcription level of the Mak gene and/or Ick gene, or the Ccrk gene can be confirmed by known techniques such as quantitative RT-PCR.
  • known techniques such as quantitative RT-PCR.
  • Those skilled in the art can appropriately design and prepare primer sequences to be used in quantitative RT-PCR, etc., based on gene sequence information obtained from known databases such as GenBank.
  • Mak and/or Ick may be Mak and/or Ick proteins, or may be polypeptides or functional fragments of Mak and/or Ick proteins.
  • the amino acid sequences of Mak and/or Ick proteins can be obtained from publicly known databases such as GenBank. For example, the amino acid sequence of human MAK (GenBank Accession No.: AAN16405.1, SEQ ID NO: 7), mouse Mak (GenBank Accession No.: CAA47392.1, SEQ ID NO: 8), human ICK (GenBank Accession No.: AAF37278.1, SEQ ID NO: 9), and mouse Ick (GenBank Accession No.: AAF37277.1, SEQ ID NO: 10) have been disclosed.
  • the polypeptides or functional fragments of Mak and/or Ick proteins may have activity similar to or improved from that of wild-type Mak and/or Ick proteins, or may mediate the protein activity of wild-type Mak and/or Ick proteins.
  • Mak and/or Ick proteins or polypeptides may be variants in which a residue is replaced by another residue with similar properties through conservative amino acid substitutions.
  • Mak and/or Ick proteins may also be part of a larger protein, such as a fusion protein, which may contain additional amino acid sequences, including secretory or leader sequences, prosequences, or other sequences that may aid stability.
  • the substance that promotes the expression or function of an upstream regulatory factor of Mak and/or Ick may be the Ccrk protein, or a polypeptide or functional fragment of the Ccrk protein.
  • the amino acid sequence of the Ccrk protein can be obtained from publicly known databases such as GenBank. For example, the amino acid sequence of human CCRK (GenBank accession number: AAC98920.1, SEQ ID NO: 11) and the amino acid sequence of mouse Ccrk (GenBank accession number: AAF89089.1, SEQ ID NO: 12) have been disclosed.
  • the polypeptide or functional fragment of the Ccrk protein can be used in the same manner as the polypeptide or functional fragment of Mak and/or Ick.
  • the methods for obtaining and preparing Mak protein and/or Ick protein or Ccrk protein are not particularly limited, and may be naturally occurring proteins, chemically synthesized proteins, or recombinant proteins produced by genetic engineering.
  • Naturally occurring Mak and/or Ick or Ccrk proteins can be obtained from cells or tissues expressing Mak protein and/or Ick protein or Ccrk protein by appropriately combining known protein isolation and purification methods. Chemical synthesis of proteins and production of recombinant proteins can be carried out by techniques known to those skilled in the art.
  • the presence or absence and degree of increase in expression of Mak and/or Ick or Ccrk at the protein level can be confirmed by known techniques such as immunohistological staining.
  • the labeled antibodies used in immunohistological staining may be commercially available antibodies, or antibodies prepared by known techniques.
  • a substance that promotes the function of Mak and/or Ick may be a substance that inhibits the activity of fibroblast growth factor receptor (hereinafter referred to as FGFR).
  • FGFR fibroblast growth factor receptor
  • four types of human FGFR have been identified: FGFR1, FGFR2, FGFR3, and FGFR4. Therefore, a substance that inhibits FGFR activity may be an FGFR inhibitor that is selective for one or more FGFRs selected from FGFR1, FGFR2, FGFR3, and FGFR4.
  • a substance that inhibits FGFR activity may be an FGFR inhibitor, an FGFR kinase inhibitor, a dominant negative form of FGFR, or a specific antibody against FGFR.
  • FGFR inhibitors include, but are not limited to, rogaratinib, apruzumab, futibatinib, derazantinib, ASP5878 (Astellas), zoligratinib, FP-1039 (GSK/FivePrime), LY-2874455 (Lilly), RG-7444 (Roche), fexagratinib (AZD4547), infigratinib (BGJ398), erdafitinib, PD173074 (Selleck), pemigatinib, compounds described in International Publication No. WO 2013/108809 A1, compounds described in Patent Publication JP 5639261 B2, and any combinations thereof.
  • FGFR inhibitors are useful as substances that promote the function of Mak and/or Ick.
  • the FGFR inhibitor which is the active ingredient in the pharmaceutical composition of the present invention, is already in clinical use, so the pharmaceutical composition of the present invention can be safely administered to humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).
  • mammals e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.
  • the daily dosage of the pharmaceutical composition of the present invention can be set in accordance with the daily dosage of FGFR inhibitors in clinical use.
  • the pharmaceutical of the present invention can be formulated by appropriately blending the above-mentioned active ingredients with pharmaceutically acceptable carriers and further additives. Specifically, it can be formulated as oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, and emulsions; or parenteral preparations such as injections, infusions, suppositories, ointments, and patches.
  • the blending ratio of the carrier or additive may be appropriately set based on the range commonly used in the pharmaceutical field.
  • carriers or additives that can be blended; examples include various carriers such as water, saline, other aqueous solvents, and aqueous or oily bases; and various additives such as excipients, binders, pH adjusters, disintegrants, absorption enhancers, lubricants, colorants, flavorings, and fragrances.
  • excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose, and light anhydrous silicic acid.
  • binders include polymeric compounds such as crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, and polyvinylpyrrolidone.
  • lubricants include magnesium stearate, calcium stearate, talc, and colloidal silica.
  • disintegrants include starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, and carboxymethylstarch sodium.
  • humectants include, but are not limited to, glycerin, butylene glycol, propylene glycol, sorbitol, and triacetin.
  • the tablet may be coated with a coating agent (sucrose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose phthalate, etc.), or may be coated with two or more layers.
  • the active ingredient can be dissolved or dispersed in an aqueous base such as physiological saline or an oily base acceptable for injection to prepare an injection for intravenous, intramuscular, subcutaneous, etc. administration.
  • aqueous base such as physiological saline or an oily base acceptable for injection to prepare an injection for intravenous, intramuscular, subcutaneous, etc. administration.
  • Additives such as buffers, pH adjusters, isotonicity agents, solubilizers, suspending agents, stabilizers, etc. can be added as needed.
  • aqueous bases include, for example, infusion solutions such as physiological saline, water for injection, and Ringer's solution.
  • Oily bases include, for example, propylene glycol, polyethylene glycol, sesame oil, soybean oil, corn oil, peanut oil, cottonseed oil, olive oil, and propylene glycol fatty acid esters.
  • Buffers include, for example, phosphates, acetates, carbonates, citrates, borates, glutamate, epsilon aminocaproate, and buffer solutions such as Tris buffer.
  • pH adjusters include, for example, inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, and carbonic acid; organic acids such as acetic acid, tartaric acid, lactic acid, citric acid, and succinic acid; inorganic bases such as sodium hydroxide; and organic bases such as sodium citrate and sodium tartrate.
  • inorganic acids such as hydrochloric acid, phosphoric acid, sulfuric acid, and carbonic acid
  • organic acids such as acetic acid, tartaric acid, lactic acid, citric acid, and succinic acid
  • inorganic bases such as sodium hydroxide
  • organic bases such as sodium citrate and sodium tartrate.
  • isotonic agents include inorganic salts such as sodium chloride, sugar alcohols such as D-mannitol, sorbitol, and xylitol, sugars such as fructose, glucose, galactose, ribose, xylose, mannose, maltotriose, and maltotetraose, and amino acids such as glycine and arginine.
  • solubilizing agents include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, lecithin, and nonionic surfactants such as polysorbate 80.
  • suspending agents examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, and glycerin monostearate, as well as polyvinyl alcohol, polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, and hydroxymethylcellulose.
  • surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, and glycerin monostearate
  • polyvinyl alcohol polyvinylpyrrolidone
  • sodium carboxymethylcellulose methylcellulose
  • hydroxymethylcellulose examples include albumin, globulin, gelatin, sorbitol, ethylene glycol, propylene glycol, ascorbic acid, etc.
  • the present invention provides a substance that promotes the expression or function of Mak and/or Ick, or a composition for improving ciliary disorders containing Mak and/or Ick as an active ingredient.
  • the present inventors have confirmed that forced expression of Mak or Ick can improve ciliary abnormalities caused by Ick deficiency (see Example 1), and that forced expression of Ick or administration of an FGFR inhibitor can improve retinal degeneration caused by Mak deficiency (see Examples 2 and 3).
  • the present inventors have also confirmed that forced expression of Ick, Mak, or Ccrk can improve ciliary disorders caused by cytoplasmic dynein inhibition (see Examples 4, 5, and 8).
  • the present inventors have confirmed that inhibition of FGFR activity can improve ciliary disorders caused by cytoplasmic dynein inhibition (see Examples 6 and 7). Therefore, the composition for improving ciliary disorders of the present invention is effective in improving or treating ciliary disorders.
  • composition for improving ciliary disorders of the present invention can contain as its active ingredient the substances described in the above-mentioned embodiments of the pharmaceutical composition. Furthermore, as described in the above-mentioned embodiments of the pharmaceutical composition, the composition for improving ciliary disorders of the present invention can be formulated into various dosage forms and can be safely administered to humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).
  • mammals e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.
  • the present invention provides a method for screening for a substance that improves cilia dysfunction.
  • the screening method of the present invention may be a method for identifying a substance that activates Mak ex vivo or in vitro, a method for identifying a substance that activates Ick ex vivo or in vitro, or a method for identifying a substance that activates Ccrk ex vivo or in vitro.
  • a method for identifying a substance that activates Mak or Ick may be a method for identifying a substance that enhances Kif3a phosphorylation.
  • a method for identifying a substance that activates Ccrk may be a method for identifying a substance that enhances Mak and/or Ick phosphorylation.
  • test substance used in the screening method of the present invention is not particularly limited, and may be a nucleic acid, peptide, protein, non-peptide compound, synthetic compound, fermentation product, cell extract, cell culture supernatant, plant extract, mammalian tissue extract, plasma, etc.
  • the test substance may be a novel substance or a known substance.
  • these test substances may form salts. Salts of test substances with physiologically acceptable acids or bases are preferred.
  • the first embodiment of the screening method of the present invention may include the following steps (1) to (3): (1): contacting Mak and Kif3a with a test substance; (2): measuring the phosphorylation of Kif3a; and (3): identifying a substance that increases the phosphorylation level of Kif3a compared to the phosphorylation level of Kif3a when the test substance is not contacted.
  • Step (1) may be a method in which a solution containing purified Mak and purified Kif3a is prepared and the test substance is added to the solution, or a method in which cells expressing Mak and Kif3a are cultured and the test substance is added to the culture medium.
  • the Mak and Kif3a used in step (1) may be derived from any organism, including mammals. Examples of mammals include humans, chimpanzees, monkeys, dogs, cows, mice, rats, and guinea pigs, with humans being preferred.
  • Cells expressing Mak and Kif3a can be produced by introducing a gene encoding Mak and a gene encoding Kif3a into suitable host cells. The produced cells expressing Mak and Kif3a are cultured, and purified Mak and purified Kif3a can be obtained from the culture supernatant or cell extract using known methods (e.g., affinity columns).
  • Amino acid sequence information for Mak and Kif3a and nucleotide sequence information for the genes encoding them can be obtained from publicly known databases (DDBJ/GenBank/EMBL, etc.).
  • the nucleotide sequence (GenBank: AF505623, SEQ ID NO: 1) and amino acid sequence (GenBank: AAN16405.1, SEQ ID NO: 7) of the entire coding region of human MAK the nucleotide sequence (GenBank: X66983, SEQ ID NO: 2) and amino acid sequence (GenBank: CAA47392.1, SEQ ID NO: 8) of the entire coding region of mouse Mak
  • the nucleotide sequence (GenBank: D12645, SEQ ID NO: 15) and amino acid sequence GeneBank: BAA02166.1, S
  • the Mak- and Kif3a-expressing cells used in step (1) may be cells expressing endogenous Mak and endogenous Kif3a, cells expressing recombinant Mak and recombinant Kif3a derived from introduced genes, or cells expressing Mak and Kif3a through a combination of endogenous and recombinant proteins. Cells expressing recombinant Mak and recombinant Kif3a are preferred. Examples of cells expressing endogenous Mak and/or endogenous Kif3a include HEK293T cells, NIH3T3 cells, hTERT-RPE1 cells, and U-251 MG cells. Host cells may be any cells capable of expressing the products of the introduced genes, and are not particularly limited.
  • Examples include mammalian cells and insect cells.
  • Examples of mammalian cells include HEK293T cells, NIH3T3 cells, Expi293 cells, and hTERT-RPE1 cells.
  • Examples of insect cells include Sf9 cells and Sf21 cells.
  • step (1) if a solution containing purified Mak and purified Kif3a is prepared and the test substance is added to the solution, the amounts of purified Mak and purified Kif3a added to the solution are not particularly limited, but may be approximately a 1:1 molar ratio.
  • the amount of test substance added is not particularly limited as long as it allows the phosphorylation level of Kif3a to be confirmed in the next step.
  • the test substance may be added at multiple concentrations within a set concentration range.
  • the solution used is not particularly limited, and known buffers that can be used in protein phosphorylation reactions can be suitably used.
  • 50 mM Tris-HCl (pH 7.5) buffer containing 1 mM CaCl2, 100 mM NaCl, 1 mg/ml BSA, 0.025% NP-40, and 1 mM DTT can be used.
  • the temperature and contact time of the solution are not particularly limited, and the solution temperature can be 37°C and the contact time can be 30 minutes, for example.
  • the amount of test substance added may be any amount that does not significantly inhibit cell growth or recombinant protein expression.
  • the test substance may be added at multiple concentrations over a range of concentrations.
  • the time period for adding the test substance is not particularly limited and may be from about 0.5 hours to about 48 hours.
  • the amount of Kif3a phosphorylation can be measured by a known method.
  • electrophoresis which can separate phosphorylated and non-phosphorylated forms, adding phosphate-labeled ATP to a solution, or using an antibody that recognizes phosphorylation may be used.
  • Phos-tag SDS-PAGE Flujifilm Wako Pure Chemical Industries, Ltd.
  • 32P -labeled ATP PerkinElmer, etc.
  • a substance that increases the phosphorylation level of Kif3a is identified.
  • a substance that increases the phosphorylation level of Kif3a may be identified by comparing the amount of Kif3a phosphorylation in a sample not contacted with the test substance (control group) with the amount of Kif3a phosphorylation in a sample contacted with the test substance (test substance group), and selecting a test substance that increases the amount of phosphorylation.
  • the degree to which a test substance increases the amount of Kif3a phosphorylation is not particularly limited.
  • a test substance that increases the amount of Kif3a phosphorylation by 120% or more, 130% or more, 140% or more, 150% or more, 170% or more, 180% or more, 190% or more, or 200% or more compared to a sample not contacted with the test substance may be selected, or a test substance that exhibits a significant difference detected by statistical processing may be selected.
  • the second embodiment of the screening method of the present invention may include the following steps (1) to (3): (1): contacting Ick and Kif3a with a test substance; (2): measuring the phosphorylation of Kif3a; and (3): identifying a substance that increases the phosphorylation level of Kif3a compared to the phosphorylation level of Kif3a in the absence of contact with the test substance.
  • Step (1) can be carried out in the same manner as step (1) of the first embodiment, except that Mak is replaced with Ick.
  • Steps (2) and (3) can be carried out in the same manner as steps (2) and (3) of the first embodiment, respectively.
  • the Ick and Kif3a used in the screening methods of the present invention may be derived from any organism, even mammals. Examples of mammals include humans, chimpanzees, monkeys, dogs, cows, mice, rats, and guinea pigs, with humans being preferred. Information on the amino acid sequences of Ick and Kif3 and the nucleotide sequences of the genes encoding them can be obtained from publicly known databases (DDBJ/GenBank/EMBL, etc.).
  • nucleotide sequence (GenBank accession number: AF225919, SEQ ID NO: 3) and amino acid sequence (GenBank accession number: AAF37278.1, SEQ ID NO: 9) of the entire coding region of human ICK
  • the third embodiment of the screening method of the present invention may include the following steps (1) to (3): (1): contacting Ccrk, Mak and/or Ick with a test substance; (2): Measuring the phosphorylation of Mak and/or Ick, and (3): Identifying a substance that increases the phosphorylation level of Mak and/or Ick compared to the phosphorylation level of Mak and/or Ick when the test substance is not contacted.
  • Step (1) can be carried out in the same manner as step (1) of the first embodiment, except that Mak and Kif3a are replaced with Ccrk and Mak and/or Ick.
  • Steps (2) and (3) can be carried out in the same manner as steps (2) and (3) of the first embodiment, except that kif3a is replaced with Mak and/or Ick in steps (2) and (3) of the first embodiment.
  • the Ccrk, Mak, and Ick used in the screening method of the present invention may be derived from any organism, even mammals. Examples of mammals include humans, chimpanzees, monkeys, dogs, cows, mice, rats, and guinea pigs, with humans being preferred. Information on the amino acid sequences of Ccrk, Mak, and Ick and the nucleotide sequences of the genes encoding them can be obtained from publicly known databases (DDBJ/GenBank/EMBL, etc.).
  • nucleotide sequence (GenBank accession number: AF035013, SEQ ID NO: 5) and amino acid sequence (GenBank accession number: AAC98920.1, SEQ ID NO: 11) of the entire coding region of human CCRK, and the nucleotide sequence (GenBank accession number: AY005133, SEQ ID NO: 6) and amino acid sequence (GenBank accession number: AAF89089.1, SEQ ID NO: 12) of the entire coding region of mouse Ccrk have been disclosed.
  • Ccrk CKO mice were generated by crossing Ccrk floxed mice with the Dkk3-Cre mice described above.
  • Ccrk floxed mice were generated as follows: an 11.5-kb Ccrk genomic fragment was subcloned by PCR using C57BL/6 genomic DNA. One loxP site was inserted into intron 2 and another loxP site was inserted into intron 4.
  • the targeting vector was then cloned into a modified pBluescript II KS(+) vector (Agilent).
  • the linearized targeting vector was transfected into the JM8A3 embryonic stem (ES) cell line (Pettitt, SJ et al. Nat Methods, 2009, 6:493-495).
  • JM8A3 cell culture, electroporation, and selection were performed as previously described (Muranishi, Y. et al. J Neurosci, 2011, 31:16792-16807).
  • Heterozygous ES cells carrying the targeted gene disruption were microinjected into C57BL/6 blastocysts to generate chimeric mice. These chimeric mice were then mated with C57BL/6 mice to generate offspring. These mice were then mated with B6-Tg(CAG-FLPe)37 mice (#RBRC01835, provided by the RIKEN BioResource Research Center) to remove the flippase recognition target (FRT)-flanking neo cassette using flippase (Flp) recombinase.
  • FRT flippase recognition target
  • Flp flippase
  • Plasmid Constructs Plasmids expressing EGFP, FLAG- or HA-tagged mouse Mak and mouse Ick, and FLAG-tagged EGFP were constructed as previously described (Chaya T et al., EMBO J, 2014, 33:1227-1242; Omori Y et al., Proc Natl Acad Sci USA, 2010, 107:22671-22676; Tsutsumi R et al., J Biol Chem, 2022, 298:101686).
  • the full-length cDNA fragment of mouse Dync2li1 was amplified by PCR using mouse retina cDNA as a template and subcloned into the pCAGGSII-3 ⁇ FLAG vector (Irie S et al., Mol Cell Biol, 2015, 35:2583-2596; Sanuki R et al., Cell Rep, 2015, 10:796-808).
  • the full-length cDNA fragment of mouse Ccrk was amplified by PCR using mouse testis cDNA as a template and subcloned into the pCAGGSII vector (Omori Y et al., Proc Natl Acad Sci USA, 2010, 107:22671-22676).
  • mouse Fgfr1 A645V was subcloned into the pCAGGSII-c-2xHA vector (Ueno A et al., Cell Reports, 2018, 22:3548-3561).
  • Dync2li1-shRNA and Control-shRNA cassettes were subcloned into the pBAsi-mU6 vector (Takara Bio).
  • each shRNA The target sequences of each shRNA are as follows: Dync2li1 shRNA2: 5'-GCTTTGTGGCACATTACTACG-3' (SEQ ID NO: 17), Dync2li1 shRNA3: 5'-GCAGGACTGGATTCTTTATGT-3' (SEQ ID NO: 18), Dync2li1 shRNA5: 5'-GGGAATTAATTGACCCATTTC-3' (SEQ ID NO: 19), Dync2li1 shRNA6: 5'-GCAAGTCAGAAGCTGTTAC-3' (SEQ ID NO: 20), Control shRNA: 5'-GACGTCTAACGGATTCGAGCT-3' (sequence number 21).
  • AAV rhodopsin kinase promoter-3 ⁇ FLAG-Ick was generated by PCR amplification of the full-length mouse Ick cDNA fragment using pCAGGSII-2 ⁇ HA-mouse Ick (Chaya T et al., EMBO J, 2014, 33:1227-1242) as a template.
  • the full-length cDNA fragment was then subcloned into the pBluescript II KS (+)-3 ⁇ FLAG vector (modified from the pBluescript II KS (+) vector (Agilent)) to generate pBluescript II KS (+)-3 ⁇ FLAG-Ick.
  • the excised 3 ⁇ FLAG-Ick fragment was then ligated into the pAAV-RK-IZsGreen vector (Khani SC et al., Invest Ophthalmol Vis Sci, 2007, 48:3954-3961).
  • HEK293T cells and NIH3T3 cells were cultured at 37°C in a 5% CO atmosphere in Dulbecco's Modified Eagle Medium (DMEM) (Sigma) containing 10% fetal bovine serum or bovine serum supplemented with penicillin (100 ⁇ g/ml) and streptomycin (100 ⁇ g/ml), respectively.
  • DMEM Dulbecco's Modified Eagle Medium
  • Ick ⁇ / ⁇ MEF cells were derived from Ick ⁇ / ⁇ mouse embryos at embryonic day 13.5 and cultured at 37° C in a 5% CO atmosphere in DMEM containing 10% fetal bovine serum, supplemented with penicillin (100 ⁇ g/ml) and streptomycin (100 ⁇ g/ml).
  • Transfection was performed by the calcium phosphate method (HEK293T cells) or by lipofection using Lipofectamine LTX (Invitrogen) or Lipofectamine 3000 (Invitrogen) (NIH3T3 cells and Ick -/- MEF cells).
  • HEK293T cells calcium phosphate method
  • Lipofectamine LTX Invitrogen
  • Lipofectamine 3000 Invitrogen
  • NIH3T3 cells were incubated for 24 hours in serum-free medium supplemented with 100 nM BGJ398 (ChemScene), 100 nM AZD4547 (MedChemExpress), 100 nM SAG (Smoothened agonist, Calbiochem), or 10 ⁇ M Ciliobrevin D (Millipore).
  • the primary antibodies used were mouse anti-acetylated ⁇ -tubulin (AcTub) antibody (1:1000 or 1:2000 dilution, Sigma, clone 6-11B-1), rabbit anti-FLAG antibody (1:1000 dilution, Sigma, product number F7425), mouse anti-FLAG M2 antibody (1:1000 dilution, Sigma, product number F1804), and rabbit anti-rhodopsin antibody (1:2500 dilution, LSL, product number LB-5597).
  • Secondary antibodies were Cy3-conjugated (1:500 dilution, Jackson ImmunoResearch Laboratories) or Alexa Fluor 488-conjugated (1:500 dilution, Sigma).
  • the specimens were observed under a confocal laser scanning microscope (LSM700, LSM710, or LSM900, Carl Zeiss). Cilia length was measured using ZEN imaging software (ZEN blue edition, Carl Zeiss). Immunofluorescence signal intensity was measured and quantified using NIH ImageJ software. The rhodopsin signal inside the photoreceptor cells was normalized to the total rhodopsin signal (outer segment and inner photoreceptor cells).
  • the primary and secondary antibodies used were the antibodies listed in Section 5 above, as well as the following: rabbit anti-IFT88 antibody (1:500 dilution, Proteintech, 13967-1-AP), guinea pig anti-Mak antibody (1:1000 dilution, Omori Y et al., PNAS, 2010, 107(52):22671-22676), and mouse anti-Cep164 antibody (clone E-9, 1:200 dilution, Santa Cruz, sc-515403). Microscopic observation and analysis were performed as described in Section 5 above.
  • Retinal Thickness Analysis of Retinal Thickness. Retinal sections were washed with PBS and stained for 1 minute in PBS containing 0.1% toluidine blue. After washing the sections with PBS, the slides were covered with a coverslip and immediately observed under a microscope. Retinal thickness was measured and quantified using NIH ImageJ software.
  • HEK293T cells were washed twice with Tris-buffered saline (TBS) and lysed in lysis buffer supplemented with protease inhibitors (Buffer A: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM PMSF, 2 ⁇ g/ml leupeptin, 5 ⁇ g/ml aprotinin, 3 ⁇ g/ml pepstatin A) or SDS sample buffer.
  • TBS Tris-buffered saline
  • protease inhibitors Buffer A: 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM PMSF, 2 ⁇ g/ml leupeptin, 5 ⁇ g/ml aprotinin, 3 ⁇ g/ml pepstatin A
  • guinea pig anti-Mak (1:150 dilution, Omori Y et al., PNAS, 2010, 107(52):22671-22676), and rabbit anti-phosphorylated Mak (pMak) (Thr1579) (1:1000 dilution, Invitrogen, PA5-105526).
  • the secondary antibodies used were horseradish peroxidase-conjugated anti-mouse IgG (1:10,000 dilution, Zymed), and horseradish peroxidase-conjugated anti-rabbit IgG (1:10,000 dilution, Jackson Laboratory).
  • Adeno-associated virus (AAV) production and subretinal injection AAV-293 cells were transfected with the AAV vector plasmid, adenovirus helper plasmid, and AAV helper plasmid (pAAV2-8 SEED) using the calcium phosphate method to produce AAV. 72 hours after transfection, cells were harvested and lysed by four freeze-thaw cycles. The supernatant was collected by centrifugation and treated with Benzonase nuclease (Novagen). Virus was purified using an iodixanol gradient.
  • Iodixanol gradients were formed in ultraclear centrifuge tubes (14 ⁇ 95 mm, Beckman) by layering 54% iodixanol (Axis-Shield) in PBS-MK buffer (1 ⁇ PBS, 1 mM MgCl2, 25 mM KCl) with 40% iodixanol, 25% iodixanol in PBS-MK buffer with phenol red, and 15% iodixanol in PBS-MK buffer with 1 M NaCl in PBS-MK buffer. The tubes were centrifuged at 40,000 rpm in an SW40Ti rotor.
  • the virus-containing fraction between 54% and 40% was collected with an 18-gauge needle and concentrated using an Amicon Ultra Centrifugal Filter Ultracel-100K (Millipore).
  • the titer (vector genomes (VG)/ml) of each AAV was measured by qPCR using SYBR GreenER Q-PCR Super Mix (Invitrogen) and a Thermal Cycler Dice Real Time System Single MRQ TP700 (Takara Bio) according to the manufacturer's protocol. Quantification was performed using the Thermal Cycler Dice Real Time System software (Takara Bio).
  • the titer of AAV-RK-N-FLAGx3-Ick was adjusted to approximately 1.8 x 10 VG/ml.
  • 0.3 ⁇ l of the AAV preparation was injected subretinally into 1-day-old (P1) Mak -/- mice. The injected retinas were harvested 14 days later (P14).
  • BGJ398 (ChemScene) was dissolved in dimethyl sulfoxide (DMSO) at 2 mg/ml or 4 mg/ml and diluted with 3.5 mM HCl and 5% DMSO. Mice were injected subcutaneously with 2 mg/kg of BGJ398 daily.
  • DMSO dimethyl sulfoxide
  • Luciferase Reporter Assay were performed using the Nano-Glo Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's protocol. To generate the reporter construct, a minimal promoter (5'-AGACACTAGAGGGTATATAATGGAAGCTCGACTTCCAG-3', SEQ ID NO: 22) and 8xGli1 binding sites were cloned into the pGL3-Basic vector (Promega), replacing firefly luciferase with NanoLuc luciferase. NanoLuc luciferase was obtained by PCR amplification from the pNLF-N[CMV/Hygro] vector (Promega).
  • the pGL3-Control vector (Promega) was used to normalize transfection efficiency.
  • NIH3T3 cells were transfected with plasmids expressing Dync2li1-shRNA2, Dync2li1-shRNA3, or Dync2li1-shRNA6, and plasmids expressing Ick, Mak iso1, Mak iso2, or Ccrk, along with reporter constructs. 24 hours after transfection, cells were incubated in serum-free medium containing 100 nM SAG for 24 hours and then washed with PBS. Luminescence signals were detected using the GloMax Multi+ Detection System (Promega).
  • Example 1 Effect of Mak overexpression in Ick-deficient cells
  • Ick -/- MEFs were transfected with plasmids encoding FLAG-tagged EGFP (control), FLAG-tagged Ick, FLAG-tagged Mak isoform 1 (Mak iso1), or FLAG-tagged Mak isoform 2 (Mak iso2), and the number and length of cilia were compared.
  • the results are shown in Figure 1.
  • (A) shows immunostaining results with anti-FLAG and anti-acetylated ⁇ -tubulin (AcTub) antibodies.
  • AcTub is a cilia marker.
  • Nuclei were stained with DAPI.
  • B) and C show the number (B) and length (C) of cilia stained with anti-AcTub antibody in FLAG-positive cells. Data are shown as mean ⁇ SD. Significance was tested by one-way analysis of variance followed by Tukey's multiple comparison test. Overexpression of Ick, Mak iso1, or Mak iso2 increased the number and length of cilia stained with anti-AcTub antibody compared with controls, indicating that not only Ick expression but also Mak expression can improve ciliary abnormalities caused by Ick deficiency.
  • OS indicates the outer segment
  • ONL indicates the outer nuclear layer.
  • FIG. 3(A) shows the results of toluidine blue staining of retinal sections prepared from 14-day-old (P14) and 1-month-old (1M) mice.
  • OS indicates the outer segment
  • ONL indicates the outer nuclear layer
  • INL indicates the inner nuclear layer
  • GCL indicates the ganglion cell layer.
  • Figure 3(B) shows the results of measuring the thickness of the outer nuclear layer (ONL). Data are shown as mean ⁇ SD. Significance was tested using an unpaired t-test. The retinal photoreceptor layer was significantly thinner in Mak/Ick DKO mouse retinas compared with controls, and photoreceptor degeneration was more severe than in Mak-deficient (Mak -/- ) mice.
  • Example 3 Effect of administration of FGFR inhibitor to Mak-deficient mice Mak -/- mice were administered an FGFR inhibitor and their effects on retinal tissue were analyzed. The results are shown in Figures 4, 5, and 6.
  • Figure 4(A) shows the drug administration schedule. Mak -/- mice were subcutaneously injected with the FGFR inhibitor BGJ398 daily from postnatal day 7 (P7) to 1 month of age (1M).
  • ONL denotes the outer nuclear layer
  • INL denotes the inner nuclear layer
  • GCL denotes the ganglion cell layer.
  • Figure 4(C) shows the thickness of the outer nuclear layer (ONL). Data are shown as mean ⁇ SD. Significance was determined by unpaired t-test. The photoreceptor layer of the retina in BGJ398-treated mice was significantly thicker than that in vehicle-treated mice, indicating that administration of an FGFR inhibitor can ameliorate retinal degeneration caused by Mak deficiency.
  • Figure 5 shows the results of electroretinogram (ERG) analysis in Mak -/- (1M) mice treated with BGJ398 or vehicle.
  • the amplitudes of the a-wave and b-wave under dark and light conditions are shown as a function of stimulus intensity (-4.0 to 1.0 log cd s/ m2 and -0.5 to 1.0 log cd s/ m2 , respectively). Data are shown as mean ⁇ SD. Significance was tested using unpaired t-tests. Analysis was performed using six dark-condition control (Vehicle) and dark-condition BGJ398-treated mice, five light-condition control (Vehicle) mice, and six light-condition BGJ398-treated mice.
  • the BGJ398-treated group demonstrated significantly higher dark-condition ERG a-waves (Fig. 5(A)) and b-waves (Fig. 5(B)). These results indicated that administration of an FGFR inhibitor can improve retinal degeneration caused by Mak deficiency.
  • Figure 6 shows the results of analyzing kinesin family 3A protein (Kif3a) phosphorylation in the retinas of Mak -/- (1M) mice treated with BGJ398 or vehicle (control). Retinas from four mice were analyzed. Retinal lysates were subjected to Phos-tag Western blotting using an anti-Kif3a antibody and standard Western blotting. The relative phosphorylation level of Kif3a was quantified by the ratio of the upper band intensity (indicated by the white arrowhead in Figure 6(A)) to the lower band intensity (indicated by the black arrowhead in Figure 6(A)). Data are shown as mean ⁇ SD. Significance was determined by unpaired t-test.
  • Kif3a is known to be a downstream molecule phosphorylated by Mak and Ick, respectively. Therefore, FGFR inhibitors can enhance Ick activity in Mak-deficient retinas.
  • Example 4 Effect of Ick overexpression in cells with ciliary disorders caused by a dynein motor protein inhibitor The effect of Ick overexpression was analyzed in cells treated with a dynein motor protein inhibitor. The results are shown in Figure 7.
  • Example 5 Effect of Ick overexpression in cells with ciliary disorders caused by knockdown of dynein motor proteins (1) Generation of Dync2li1 Knockdown Cells.
  • dvsnc2li1 dynein motor protein
  • Dync2li1 dynein cytoplasmic 2 light intermediate chain 1
  • a subunit of the cytoplasmic dynein 2 complex compared their inhibitory effects.
  • HEK293T cells were co-transfected with plasmids encoding control (Control-shRNA) or Dync2li1-specific shRNAs (Dync2li1-shRNA2, Dync2li1-shRNA3, Dync2li1-shRNA5, or Dync2li1-shRNA6) and plasmids expressing FLAG-tagged Dync2li1 and EGFP.
  • Western blot analysis was performed using anti-FLAG and anti-GFP antibodies. GFP was used as an internal control for transfection. The results are shown in Figure 8.
  • Example 6 Effect of FGFR inhibition on cells with ciliary disorders caused by knockdown of dynein motor proteins Dync2li1 knockdown cells were generated and the effect of FGFR activity inhibition on ciliary dysfunction was examined.
  • NIH3T3 cells were transfected with a plasmid expressing FLAG-tagged EGFP and a plasmid expressing either control-shRNA or Dync2li1-shRNA3 and treated with DMSO or BGJ398 (100 nM) for 24 hours. The results are shown in Figure 10.
  • Example 7 Effect of Ick or Mak overexpression on hedgehog signaling abnormalities in ciliary disorders
  • Ciliary disorders are known to cause abnormalities in Hedgehog signaling.
  • luciferase reporter gene assays using an 8xGli1-binding site-minimal promoter-NanoLuc luciferase construct. The results are shown in Figure 13.
  • (A) A schematic diagram of the construct expressing NanoLuc luciferase under the control of 8xGli1-binding sites and a minimal promoter.
  • NIH3T3 cells were transfected with a Dync2li1-shRNA2 expression plasmid, an Ick expression plasmid, a NanoLuc luciferase reporter construct driven by 8xGli1-binding sites and a minimal promoter, and a firefly luciferase expression construct driven by the SV40 promoter and enhancer.
  • NIH3T3 cells were transfected with a Dync2li1-shRNA2 expression plasmid, a Mak iso1 or Mak iso2 expression plasmid, a Nanoluc luciferase reporter construct driven by an 8x Gli1 binding site and minimal promoter, and a firefly luciferase expression construct driven by an SV40 promoter and enhancer.
  • Luciferase activity in cell lysates was measured after 24 hours of serum starvation following treatment with 100 nM smoothened agonist (SAG). Nanoluc luciferase activity was normalized to firefly luciferase activity. Data are shown as mean ⁇ SD.
  • Dync2li1 knockdown cells expressing Ick (B) or Mak (C) showed activity comparable to that of the control cells, indicating that expression of Ick or Mak normalizes the Hedgehog signaling abnormalities observed in ciliary disorders caused by Dync2li1 knockdown.
  • FIG. 14(A) shows the results of toluidine blue staining of retinal sections prepared from 14-day-old (P14) and 1-month-old (1M) mice.
  • ONL denotes the outer nuclear layer
  • INL denotes the inner nuclear layer
  • GCL denotes the ganglion cell layer.
  • Figure 14(B) shows the results of measuring the thickness of the outer nuclear layer (ONL). Data are shown as mean ⁇ SD. Significance was tested using an unpaired t-test. In Ccrk CKO mice, the retinal photoreceptor layer was significantly thinner than in wild-type mice, and severe photoreceptor degeneration similar to that observed in Mak/Ick DKO mice (Reference Example 1, Figure 3) was observed.
  • Figure 15 shows the results of immunostaining retinal sections prepared from 14-day-old (P14) wild-type and Ccrk CKO mice with anti-IFT88 and anti-acetylated ⁇ -tubulin (AcTub) antibodies (top row), anti-Mak and anti-AcTub antibodies (middle row), and anti-IFT88 and anti-Cep164 (centriolar protein 164) antibodies (bottom row). Nuclei were stained with DAPI. In the Ccrk CKO mouse retinas, the length of cilia was significantly shortened, and only the base of the cilia was observed, with no axonemes observed.
  • Figure 16 shows the results of analyzing Mak phosphorylation levels in the retinas of Ccrk CKO mice.
  • Western blotting of retinal lysates using anti-phosphorylated Mak (pMak) antibody and Mak antibody showed that phosphorylation of threonine 157 of Mak was reduced in the retinas of Ccrk CKO mice. From these results, the inventors discovered that Ccrk is a major upstream regulator of Mak and Ick.
  • Example 8 Effect of Ccrk overexpression in cells with ciliary disorders caused by knockdown of dynein motor proteins (1) Overexpression of Ccrk in Dync2li1-Knockdown Cells. Dync2li1-knockdown cells were generated, overexpressed Ccrk, and cilia length was measured. The results are shown in Figure 17.
  • (A) Plasmids encoding Control-shRNA or Dync2li1-shRNA3 were co-transfected into NIH3T3 cells in combination with a plasmid expressing FLAG-tagged Ccrk or a construct encoding FLAG-tagged EGFP. Immunostaining was performed with anti-FLAG and anti-AcTub antibodies.
  • Nuclei were stained with DAPI.
  • Dync2li1 knockdown significantly increased cilia length, whereas Ccrk overexpression significantly decreased cilia length.
  • Luciferase reporter gene assay A luciferase reporter gene assay was performed. The results are shown in Figure 18.
  • NIH3T3 cells were transfected with plasmids expressing Dync2li1-shRNA2 and Ccrk, a Nanoluc luciferase reporter construct driven by an 8x Gli1 binding site and minimal promoter, and a firefly luciferase expression construct driven by an SV40 promoter and enhancer. Luciferase activity in cell lysates was measured after 24 hours of serum starvation following treatment with 100 nM SAG. Nanoluc luciferase activity was normalized to firefly luciferase activity. Analysis was performed using samples from four experiments.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
PCT/JP2025/005361 2024-02-19 2025-02-18 繊毛病治療用医薬組成物 Pending WO2025178019A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026502615A JPWO2025178019A1 (cg-RX-API-DMAC7.html) 2024-02-19 2025-02-18

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024023163 2024-02-19
JP2024-023163 2024-02-19

Publications (1)

Publication Number Publication Date
WO2025178019A1 true WO2025178019A1 (ja) 2025-08-28

Family

ID=96847215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/005361 Pending WO2025178019A1 (ja) 2024-02-19 2025-02-18 繊毛病治療用医薬組成物

Country Status (2)

Country Link
JP (1) JPWO2025178019A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025178019A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物及びその塩
JP2022519131A (ja) * 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ(gcs)阻害剤を使用した繊毛病の処置
JP2022522412A (ja) * 2019-02-14 2022-04-19 エスリス ゲーエムベーハー 繊毛病の治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013108809A1 (ja) * 2012-01-19 2013-07-25 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物及びその塩
JP2022519131A (ja) * 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ(gcs)阻害剤を使用した繊毛病の処置
JP2022522412A (ja) * 2019-02-14 2022-04-19 エスリス ゲーエムベーハー 繊毛病の治療

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
KUNOVA BOSAKOVA MICHAELA, NITA ALEXANDRU, GREGOR TOMAS, VARECHA MIROSLAV, GUDERNOVA IVA, FAFILEK BOHUMIL, BARTA TOMAS, BASHEER NEH: "Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 116, no. 10, 5 March 2019 (2019-03-05), pages 4316 - 4325, XP093346869, ISSN: 0027-8424, DOI: 10.1073/pnas.1800338116 *
MARTIN LUDOVIC, KACI NABIL, ESTIBALS VALENTIN, GOUDIN NICOLAS, GARFA-TRAORE MERIEM, BENOIST-LASSELIN CATHERINE, DAMBROISE EMILIE, : "Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, vol. 27, no. 1, 1 January 2018 (2018-01-01), pages 1 - 13, XP093346867, ISSN: 0964-6906, DOI: 10.1093/hmg/ddx374 *
MAURYA ASHISH KUMAR, ROGERS TRAVIS, SENGUPTA PIALI: "A CCRK and a MAK Kinase Modulate Cilia Branching and Length via Regulation of Axonemal Microtubule Dynamics in Caenorhabditis elegans", CURRENT BIOLOGY, CURRENT SCIENCE, GB, vol. 29, no. 8, 1 April 2019 (2019-04-01), GB , pages 1286 - 1300.e4, XP093346873, ISSN: 0960-9822, DOI: 10.1016/j.cub.2019.02.062 *
OH YOON SEON, WANG ERIC J., GAILEY CASEY D., BRAUTIGAN DAVID L., ALLEN BENJAMIN L., FU ZHENG: "Ciliopathy-Associated Protein Kinase ICK Requires Its Non-Catalytic Carboxyl-Terminal Domain for Regulation of Ciliogenesis", CELLS, MDPI AG, vol. 8, no. 7, pages 677, XP093346870, ISSN: 2073-4409, DOI: 10.3390/cells8070677 *
OMORI YOSHIHIRO, CHAYA TARO, KATOH KIMIKO, KAJIMURA NAOKO, SATO SHIGERU, MURAOKA KOICHIRO, UENO SHINJI, KOYASU TOSHIYUKI, KONDO MI: "Negative regulation of ciliary length by ciliary male germ cell-associated kinase (Mak) is required for retinal photoreceptor survival", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 52, 28 December 2010 (2010-12-28), pages 22671 - 22676, XP093346872, ISSN: 0027-8424, DOI: 10.1073/pnas.1009437108 *
RYOTARO TSUTSUMI: "1T14a-12 Creation of a Novel Ciliary Disease Model Mouse Using Genome Editing and Elucidation of its Molecular Pathogenic Mechanism", ABSTRACTS OF THE 94TH ANNUAL MEETING OF THE JAPANESE BIOCHEMICAL SOCIETY; NOVEMBER 3-5, 2021, 1 January 2021 (2021-01-01), JP, pages P427, XP009566676 *

Also Published As

Publication number Publication date
JPWO2025178019A1 (cg-RX-API-DMAC7.html) 2025-08-28

Similar Documents

Publication Publication Date Title
JP6827320B2 (ja) LCA−8及び進行性RPを治療するための組換えAAV−Crumbsホモログ組成物及び方法
CN105209619B (zh) miR-204和miR-211及其用途
RU2664673C2 (ru) Векторы, кодирующие фактор жизнеспособности колбочек, полученный из палочек
US7470673B2 (en) Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
JP2003176236A (ja) 疾患の治療的処置および予防のためにbcl−2を用いる方法
JP7193874B2 (ja) 筋肉Aキナーゼアンカータンパク質(mAKAP)作用の阻害による心臓病の処置
JP2018509154A (ja) X連鎖性網膜色素変性症の治療のためのrp2及びrpgrベクター
KR20230159847A (ko) 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법
JP6467070B2 (ja) 変異dkk2タンパク質、それをコードする核酸、その製造方法、及びその用途
US20130336988A1 (en) Methods for treating early stage or mild neurological disorders
US12496328B2 (en) Compositions for the treatment of sarcopenia or disuse atrophy
JP2002087983A (ja) 筋萎縮性側索硬化症治療剤
US7053200B1 (en) Compositions and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis, and abnormal cell proliferation
WO2023006412A1 (en) Sigma-1 receptor activator for use in the treatment of a pathology associated with wfs1 mutation
US20090169540A1 (en) Use Of An Antagonist Of Epac For Treating Human Cardiac Hypertrophy
JPWO2004006956A1 (ja) 脳損傷の予後改善薬とそのスクリーニング方法
US20210236532A1 (en) Therapeutic agent for frontotemporal lobar degeneration, method for screening therapeutic agent for frontotemporal lobar degeneration and method for treating frontotemporal lobar degeneration
CA3119402A1 (en) Relaxin receptor 1 for use in treatment and prevention of heart failure
US12233050B2 (en) Drug and gene therapy to treat high myopia and other ocular disorders with enlarged eye globes
JP2004502444A (ja) 筋選択的カルシニューリン相互作用タンパク質(mcip)に関連する方法および組成物
US20230135501A1 (en) Gene therapy
US20260124275A1 (en) Methods of treating diabetes and related complications
JPWO2007043629A1 (ja) エフリンb2を用いる血管新生の抑制方法
CN108697772B (zh) 用于治疗视网膜病的组合物和方法
WO2025049923A2 (en) Novel treatments of ciliopathies

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2026502615

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2026502615

Country of ref document: JP